Market overview for Cystic Fibrosis Therapeutics Market Oct-2016

Global Cystic Fibrosis Therapeutics Market 2016-2020

Global Cystic Fibrosis Therapeutics Market 2016-2020 is the latest addition to Sandlerresearch.org
industry research reports collection.
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is
progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth.
The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and
secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are
pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very
rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with
respiratory complications, difficulties related to digestion, and anomalies in height and growth. The
mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.
The analysts forecast Global Cystic Fibrosis Therapeutics Market to grow at a CAGR of 31.9% during the
period 2016-2020.
Covered in this Report
This report covers the present scenario and the growth prospects of the global Cystic Fibrosis
Therapeutics Market for 2016-2020.
Inquire for more information @ http://www.sandlerresearch.org/inquire-beforebuying?rname=61494
Key regions
Americas
APAC
EMEA
Key vendors
AbbVie
F. Hoffmann-La Roche
Gilead Sciences
Novartis
Vertex Pharmaceuticals
Other prominent vendors
Advanced Inhalation Therapies (AIT)
Alaxia SAS
Alcresta Therapeutics